Literature DB >> 27315511

Correlations between complement system's activation factors and anti-angiogenesis factors in plasma of patients with early/late-onset severe preeclampsia.

Yingdong He1, Bingning Xu1, Di Song2,3,4,5, Feng Yu2,3,4,5, Qian Chen1, Minghui Zhao2,3,4,5,6.   

Abstract

OBJECTIVE: To investigate the expression of complement system's activation factors in plasma of patients with severe preeclampsia and their correlations with anti-angiogenesis factors.
METHODS: A case-control study was performed. The study group consisted of 30 cases of early-onset severe preeclampsia (EOSPE) and 30 cases of late-onset severe preeclampsia (LOSPE). Thirty cases were selected as the early-onset control group (E-control) and 30 as the late-onset control group (L-control), with the weeks of gestation matched. Enzyme-linked immunosorbent assay (ELISA) was used to test C3a, C5a, MAC, sEng, and sflt-1 in the maternal peripheral circulation.
RESULTS: The complement system's activation factors C3a, C5a, and MAC were increased significantly in EOSPE and LOSPE (all P < 0.01) compared with E/L-control. Plasma levels of C3a correlated inversely with plasma sEng (r = -0.454, P < 0.001) and sflt-1 (r = -0.326, P = 0.011) in preeclampsia patients, while MAC correlated with soluble endoglin (sEng; r = 0.343, P = 0.007) and soluble fms-like tyrosine kinase-1 (sflt-1; r = 0.318, P = 0.013). There were no significant correlations between complement system's activation-related factors and the anti-angiogenesis factors in healthy control group.
CONCLUSIONS: Abnormal activation of the complement system exists in the maternal circulation of patients with E/L-onset severe preeclampsia. There were correlations between the abnormal activation of the complement system and the abnormal expression of anti-angiogenesis factors in patients with severe preeclampsia, but the correlation was not strong.

Entities:  

Keywords:  Anti-angiogenesis factors; complement system’s activation factors; preeclampsia

Mesh:

Substances:

Year:  2016        PMID: 27315511     DOI: 10.1080/10641955.2016.1190845

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  3 in total

1.  Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia.

Authors:  Jennifer L Sones; Audrey A Merriam; Angelina Seffens; Dex-Ann Brown-Grant; Scott D Butler; Anna M Zhao; Xinjing Xu; Carrie J Shawber; Jennifer K Grenier; Nataki C Douglas
Journal:  FASEB J       Date:  2018-01-08       Impact factor: 5.191

2.  Celecoxib restores angiogenic factor expression at the maternal-fetal interface in the BPH/5 mouse model of preeclampsia.

Authors:  Dorien Reijnders; Chin-Chi Liu; Xinjing Xu; Anna M Zhao; Kelsey N Olson; Scott D Butler; Nataki C Douglas; Jenny L Sones
Journal:  Physiol Genomics       Date:  2018-03-09       Impact factor: 3.107

3.  Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.

Authors:  Louise C Kenny; Douglas B Kell
Journal:  Front Med (Lausanne)       Date:  2018-01-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.